Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia
Phase 3
Completed
- Conditions
- Mixed DyslipidemiaHypercholesterolemia
- Registration Number
- NCT00136799
- Lead Sponsor
- Novartis
- Brief Summary
The purpose of the study is to evaluate the safety and tolerability of fluvastatin 80 mg in a Chinese population. This study is not recruiting patients in the US.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 325
Inclusion Criteria
- Mixed dyslipidemia
- Primary hypercholesterolemia
Exclusion Criteria
- Pregnant or lactating women
- Age > 18 years
Other protocol-defined inclusion and exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percent change from baseline in low density lipoprotein cholesterol after 12 weeks
- Secondary Outcome Measures
Name Time Method Percent change from baseline in total cholesterol after 12 weeks Percent change from baseline in high density lipoprotein cholesterol after 12 weeks Percent change from baseline in total triglycerides after 12 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which fluvastatin modulates lipid metabolism in mixed dyslipidemia and primary hypercholesterolemia patients?
How does the efficacy of fluvastatin 80 mg compare to other statins in treating dyslipidemia in Asian populations?
What biomarkers are associated with response to fluvastatin in patients with familial hypercholesterolemia or metabolic syndrome?
What are the potential adverse events of high-dose fluvastatin in Chinese patients and how are they managed?
How do fluvastatin's pleiotropic effects influence cardiovascular outcomes in hypercholesterolemia compared to ezetimibe or PCSK9 inhibitors?
Trial Locations
- Locations (1)
Novartis
🇨🇳Shangai, China
Novartis🇨🇳Shangai, China